|

Fludarabine Clinical Trials

190 actively recruiting trials across 43 locations

Also known as: 2-Fluoro-9-beta-arabinofuranosyladenine, 2-Fluorovidarabine, 2-Fluorovidarabine, 21679-14-1, 21679-14-1, 9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine +19 more

Pipeline

Early 1: 7Phase 1: 82Phase 2: 41Phase 3: 6Phase 1/2: 48Phase 2/3: 2

Top Sponsors

  • National Cancer Institute (NCI)19
  • Fred Hutchinson Cancer Center12
  • St. Jude Children's Research Hospital9
  • M.D. Anderson Cancer Center9
  • Chinese PLA General Hospital9

Indications

  • Cancer177
  • Acute Myeloid Leukemia19
  • Acute Lymphoblastic Leukemia14
  • Non-hodgkin Lymphoma11
  • Myelodysplastic Syndrome11

Other54 trials

A Phase 1 Study of ADI-001 in Rheumatoid Arthritis
Phase 1
A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL
Phase 1
A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
Phase 1
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
Early 1
A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma
Phase 2
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
Phase 2
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
Early 1
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
Phase 2
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Phase 2/3
Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
Phase 2
Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
Phase 1/2
Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies
Early 1
Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
N/A
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Phase 1/2
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Phase 1/2
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
Phase 1/2
CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)
Phase 1/2
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
Phase 1
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
Phase 1
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Phase 1
HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
Phase 1/2
Immunotherapy for the Treatment of Advanced Solid Tumor
Phase 1/2
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
Phase 3
Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL
Phase 2/3
MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal Tumors
N/A
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
Phase 3
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Phase 1/2
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
Phase 1
Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
Phase 1/2
Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors
Phase 1/2
Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies
Phase 1
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Phase 1
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Phase 1
QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Phase 1
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
Early 1
Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT
Phase 2
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
Phase 1/2
Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation
Phase 2
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Phase 1/2
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Phase 1/2
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
Phase 1
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
Phase 1/2
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
Phase 1
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Phase 1/2
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Phase 1/2
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
Phase 1/2
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
Phase 1/2
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
Phase 1/2
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
Phase 1/2
TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
Phase 1/2
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Phase 1/2
Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T
Early 1
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
Early 1
Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation
Phase 1

Bethesda, Maryland17 trials

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

National Institutes of Health Clinical Center

Phase 2
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

National Institutes of Health Clinical Center

Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

National Institutes of Health Clinical Center

Phase 1/2
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

National Institutes of Health Clinical Center

Phase 1/2
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

National Institutes of Health Clinical Center

Phase 1/2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center

Phase 2
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

National Institutes of Health Clinical Center

Phase 1/2
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

National Institutes of Health Clinical Center

Phase 1
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

National Institutes of Health Clinical Center

Phase 1
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center

Phase 1/2
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

National Institutes of Health Clinical Center

Phase 1/2
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

National Institutes of Health Clinical Center

Phase 1
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

National Institutes of Health Clinical Center

Phase 1
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

National Institutes of Health Clinical Center

Phase 2
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center

Phase 1
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

National Institutes of Health Clinical Center

Phase 1/2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center

Phase 2

Duarte, California10 trials

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1
CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children

City of Hope Medical Center

Phase 1
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

City of Hope Medical Center

Phase 1
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

City of Hope Medical Center

Phase 1
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

City of Hope Comprehensive Cancer Center

Phase 1
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

City of Hope Medical Center

Phase 1
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

City of Hope

Phase 1/2
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

Phase 2

Houston, Texas10 trials

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

MD Anderson Cancer Center

Phase 1/2
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

The University of Texas M. D. Anderson Cancer Center

Phase 1/2
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

M D Anderson Cancer Center

Phase 1/2
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

The University of Texas M. D. Anderson Cancer Center

Phase 2
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

MD Anderson Cancer Center

Phase 1
Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

MD Anderson Cancer Center

Phase 1
Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

The University of Texas M. D. Anderson Cancer Center

Phase 1
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

M D Anderson Cancer Center

Phase 1/2
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Texas Children's Cancer and Hematology Center

Early 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

M D Anderson Cancer Center

Phase 1/2

Seattle, Washington10 trials

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

Fred Hutch/University of Washington Cancer Consortium

Phase 1
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Fred Hutch/University of Washington Cancer Consortium

Phase 1
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Fred Hutch/University of Washington Cancer Consortium

Phase 1
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial

Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

Phase 1
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Memphis, Tennessee9 trials

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

St. Jude Children's Research Hospital

Phase 1
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

St. Jude Children's Research Hospital

Phase 2
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

St. Jude Children's Research Hospital

Phase 1
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

St Jude Children's Research Hospital

Phase 1
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

St. Jude Children's Research Hospital

Phase 1
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

St. Jude Children's Research Hospital

Phase 1
Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

St. Jude Children's Research Hospital

Phase 1
Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

St. Jude Children's Research Hospital

Phase 1
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

St. Jude Children's Research Hospital

Phase 1

Birmingham, Alabama8 trials

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Local Institution - 0009

Phase 2
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

University of Alabama at Birmingham

Phase 1
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

University of Alabama at Birmingham

Phase 3
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)

University of Alabama at Birmingham: The Kirklin Clinic

Phase 1
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

University of Alabama at Birmingham

Phase 1
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Children's Hospital of Alabama

Phase 1
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

University of Alabama at Birmingham

Phase 1
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

University of Alabama at Birmingham Cancer Center

Phase 2

Gilbert, Arizona6 trials

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Banner MD Anderson Cancer Center

Phase 3
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Banner MD Anderson Cancer Center

Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL

Banner MD Anderson Cancer Center

Phase 2
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Banner MD Anderson Cancer Center

Phase 1
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Banner MD Anderson Cancer Center

Phase 1
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Banner MD Anderson Cancer Center

Phase 1

Boston, Massachusetts6 trials

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Boston Children's Hospital

Phase 1
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Local Institution - 0041

Phase 1
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Massachusetts General Hospital

Phase 1
IS-free Treg HaploHCT

Dana Farber Cancer Institute

Phase 1
TIL Therapy in cSCC and MCC

Dana-Farber Cancer Institute

Phase 2
TriPRIL CAR T Cells in Multiple Myeloma

Massachusetts General Hospital Cancer Center

Phase 1

Chapel Hill, North Carolina5 trials

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Lineberger Comprehensive Cancer Center

Phase 1
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill

Phase 1/2
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Lineberger Comprehensive Cancer Center at University of North Carolina

Phase 2
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

University of North Carolina

Phase 1
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Lineberger Comprehensive Cancer Center at University of North Carolina

Phase 1

Los Angeles, California4 trials

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Children's Hospital Los Angeles

Phase 1/2
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Valkyrie Clinical Trials

Phase 1/2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Children's Hospital of Los Angeles

Phase 2
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Children's Hospital Los Angeles

Phase 1

Tampa, Florida4 trials

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

Moffitt Cancer Center

Phase 2
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Moffitt Cancer Center

Phase 1
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

Moffitt Cancer Center

Phase 1/2
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Moffitt Cancer Center

Phase 2

Minneapolis, Minnesota4 trials

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center at University of Minnesota

Phase 2
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

University of Minnesota Masonic Cancer Center

Phase 1
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

University of Minnesota Masonic Cancer Center

Phase 2
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

University of Minnesota Masonic Cancer Center

N/A

San Francisco, California3 trials

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Research Site

Phase 1/2
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco

Phase 1
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

University of California, San Francisco

Phase 1

New York, New York3 trials

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Memorial Sloan Kettering Cancer Center

Phase 3
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Memorial Sloan Kettering Cancer Center

Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Memorial Sloan Kettering Cancer Center

Phase 2

Palo Alto, California2 trials

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

Lucile Packard Children's Hospital

Phase 1/2
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

Lucile Packard Children's Hospital Stanford

Phase 1

Stanford, California2 trials

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Local Institution - 307

Phase 2
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Stanford University

Phase 1

Atlanta, Georgia2 trials

CAR T-cell Therapy in Patients With Renal Dysfunction

Caitlin Guzowski

Phase 2
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Emory - Winship Cancer Institute

Phase 1

Rochester, Minnesota2 trials

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Mayo Clinic in Rochester

Phase 1
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic in Rochester

Phase 2

St Louis, Missouri2 trials

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

Washington University School of Medicine

Phase 1
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Washington University School of Medicine

Phase 1/2

Cleveland, Ohio2 trials

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Phase 2
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute

Phase 1

Columbus, Ohio2 trials

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1

Pittsburgh, Pennsylvania2 trials

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

UPMC Presbyterian

Phase 1/2
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

UPMC Children's Hospital of Pittsburgh

Phase 2

Phoenix, Arizona1 trial

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Phoenix Children's Hospital

Phase 3

Tucson, Arizona1 trial

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Banner University Medical Center - Tucson

Phase 2

Fullerton, California1 trial

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Providence Medical Foundation

Phase 1

Irvine, California1 trial

Study of LYL314 in Aggressive Large B-Cell Lymphoma

University of California-Irvine Medical Center

Phase 1/2

Orange, California1 trial

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

Chao Family Comprehensive Cancer Center, University of California Irvine

Phase 2

Redwood City, California1 trial

A Phase 1 Study of ADI-001 in Autoimmune Disease

Adicet Clinical Trials

Phase 1

Sacramento, California1 trial

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

University of California, Davis Comprehensive Cancer Center

Phase 1

San Diego, California1 trial

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

University of California San Diego

Phase 1

Aurora, Colorado1 trial

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

University of Colorado Anschutz Medical Campus

Phase 1

Washington D.C., District of Columbia1 trial

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center

Phase 2

Jacksonville, Florida1 trial

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Mayo Clinic in Florida

Phase 1

Orlando, Florida1 trial

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

AdventHealth Orlando

Phase 1

Plantation, Florida1 trial

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

IRIS Research and Development, LLC

Phase 1

Chicago, Illinois1 trial

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

University of Illinois

Phase 1

Baltimore, Maryland1 trial

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering at Basking Ridge (Consent only)

Phase 2

Rochester, New York1 trial

Umbilical Cord Blood Transplantation From Unrelated Donors

Wilmot Cancer Institute

Charlotte, North Carolina1 trial

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Novant Health Cancer Institute

Phase 1/2

Portland, Oregon1 trial

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

OHSU Knight Cancer Institute

Phase 2

Philadephia, Pennsylvania1 trial

Two Step Haplo With Radiation Conditioning

Sidney Kimmel Cancer Center at Thomas Jefferson University

Phase 2

Milwaukee, Wisconsin1 trial

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Children's Wisconsin

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.